Synthesis and pharmacological activity of adaprolol enantiomers: A new soft drug for treating glaucoma

Journal of Ocular Pharmacology and Therapeutics

Volumn 12, Issue 2, 1996, Pages 115-122

  Boder, N ^a   Elkoussi, A ^a   Zuobi, K ^a   Kovacs, P ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPROLOL MALEATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; ENANTIOMER; GLAUCOMA; NONHUMAN; STEREOCHEMISTRY;

EID: 0030009938     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1996.12.115     Document Type: Article

References (19)

1. Alkondon, M., Ray, A., and Sen, P. Autonomic regulation involved in the ocular hypotensive action of beta-adrenergic blocking agents. J. Pharm. Pharmacol. 38(4):319-322, 1986.
2. Boucher, M., Duchene-Marullaz, P., and Moundanga, J.L Studies on the stereoisomerism of beta-adrenoceptor antagonists in conscious A-V blocked dogs. Br. J. Pharmacol. 89(1):119-127, 1986.
3. Gomoll, A.W., and Bartek, M.J. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. Eur. J. Pharmacol. 132(2-3):123-135, 1986.
4. Kwan, Y.W., Socla, A.M., Gwitt, M., Kane, K.A., and Wadsworth, R.M. Comparative antifibrillatory effects of d- and dl-sotalol in normal and ischemic ventricular muscle of the cat. J. Cardiovascular Pharmacol. 15(2):233-238, 1990.
5. 1-blocking potency of S- and R-metoprolol. Br. J. Pharmacol. 99(3):592-596, 1990.
6. Keates, E., and Stone, R. The effect of d-timolol on intraocular pressure in patients with ocular hypertension. Am. J. Ophthalmol. 98:73-78, 1984.
7. Richards, R., and Tattersfield, A.E. Undesired action of timolol racemates. Br. J. Pharmacol. 20:459-462, 1985.
8. Bodor, N. The soft drug approach. Chemtech 14:28-38, 1984.
9. Bodor, N., and Elkoussi, A. Novel "soft" β-blockers as potential and safe antiglaucoma agents. Current Eye Research 7(4):369-374, 1988.
10. Bodor, N., Elkoussi, A., Kano, M., and Khalifa, M. Soft drugs VII: Soft β-blockers for systemic and ophthalmic use. J. Med. Chem. 31:1651-1656, 1988.
11. Polgar, P., and Bodor, N. Cardiac electrophysiologic effects of adaprolol maleate, a new β-blocker, in closed chest dogs. Life Sci. 48:1519-1528, 1991.
12. Sedman, A. J., and Gal, J. Resolution of the enantiomers of propranolol and other beta-adrenergic antagonists by high-performance liquid chromatography. J. Chromatography 278:199-203, 1983.
13. Karhuvaara, S., Kaila, T., and Huupponen, R. β-adrenoceptor antagonist activities and binding affinities of timolol enantiomers in rat atria. J. Pharm. Pharmacol. 40(9):649-650, 1989.
14. Schoenwald, R.D., and Huang, H.S. Corneal penetration behavior of β-blocking agents II: Assessment of barrier contributions. J. Pharm. Sci. 72:1272-1279, 1983.
15. Korolkovas, A. Essentials of Medicinal Chemistry (second ed.). John Wiley & Sons, New York, 1988.
16. VanBuskirk, E.M., and Fraunfelder, F.T. Ocular beta-blockers and systemic effects. Am J. Ophthalmol. 98:623-624, 1984.
17. Nathanson, J.A. Stereospecificity of beta adrenergic antagonists: R-enantiomers show increased selectivity for beta-2 receptors in ciliary process. J. Pharmacol Exp. Therap. 245:94-101, 1988.
18. Fassihi, A.R. Racemates and enantiomers in drug development. Int. J. Pharm. 92:1-14, 1993.
19. Ariens, E.J. Chirality in bioactive agents and its pitfalls. Trends Pharmacol. Sci. 7:200-205, 1986.